OTLC Oncotelic Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 908259 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY14,923.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE181.6%
ROA117.3%
ROIC (approx.)-3.2%
Asset turnover—
Leverage & solvency
Liabilities / assets33.4%
Debt / equity0.00x
Current ratio0.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.01x
Accruals ratio118.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $70,000 | — | — |
| R&D expense | $4,357 | — | $61,143 | $756,910 | $3.66M |
| SG&A expense | $3.18M | $376,013 | $573,726 | $4.85M | $5.47M |
| Operating income | -$3.19M | -$3.58M | -$6.65M | -$9.72M | -$9.13M |
| Interest expense | — | — | $1.04M | $2.97M | $2.00M |
| Pretax income | $360.57M | -$4.78M | — | — | — |
| Income tax | $111.55M | — | — | — | — |
| Net income | $249.28M | -$4.52M | -$7.90M | $5.09M | -$9.39M |
| EBITDA | — | — | — | — | -$9.12M |
| EPS (basic) | 0.59 | 0.01 | -0.02 | 0.01 | -0.03 |
| EPS (diluted) | 0.59 | -0.01 | -0.02 | 0.01 | -0.03 |
| Weighted avg. shares (diluted) | 422.23M | 404.40M | 396.17M | 457.30M | 303.08M |
| Balance sheet | |||||
| Cash & equivalents | $88,857 | $86,128 | $170,405 | $241,452 | $568,769 |
| Receivables | $51,324 | $18,976 | $18,976 | $19,748 | $19,748 |
| Current assets | $1.20M | $134,211 | $271,737 | $303,164 | $627,295 |
| Goodwill | $2.79M | $2.79M | $5.99M | $12.07M | $21.06M |
| Intangibles | — | — | — | — | $821,841 |
| Total assets | $393.09M | $26.68M | $30.01M | $36.12M | $23.61M |
| Current liabilities | $18.14M | $19.20M | $16.50M | $16.92M | $15.45M |
| Short-term debt | — | $2.42M | $1.77M | $390,050 | $359,262 |
| Total liabilities | $131.36M | $19.20M | $18.40M | $16.92M | $15.45M |
| Shareholders' equity | $262.76M | $8.25M | $12.13M | $19.41M | $7.96M |
| Shares outstanding | 442.60M | 407.29M | 399.18M | 391.85M | 375.29M |
| Cash flow statement | |||||
| Operating cash flow | -$1.38M | -$740,277 | -$1.32M | -$1.45M | -$4.43M |
| Financing cash flow | $1.39M | $656,000 | $1.25M | $1.13M | $4.53M |
| Depreciation & amortization | — | — | — | — | $10,148 |
| Stock-based compensation | $2.38M | $0 | $0 | $902,141 | $763,315 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.